Logo
x

Search

Subscribe Now

ovartis

Novartis Reports the US FDA’s Accelerated Approval of Fabhalta to Treat Primary IgA Nephropathy (IgAN)

Novartis Reports the US FDA’s Accelerated Approval of Fabhalta to Treat Primary IgA Nephropathy (IgAN)

  • August 9, 2024
Top 20 Biopharma M&A of 2024 by Total Deal Value

    Top 20 Biopharma M&A of 2024 by Total Deal Value

    • February 6, 2025
    Dawn Health & Novartis Introduce Cora BC to Support Breast Cancer Patients

      Dawn Health & Novartis Introduce Cora BC to Support Breast Cancer Patients

      • February 5, 2025
      Key Takeaways of J.P. Morgan Healthcare Conference 2025

        Key Takeaways of J.P. Morgan Healthcare Conference 2025

        • January 28, 2025
        Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment

          Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment

          • January 10, 2025
          Novartis Reports Data from P-III (STEER) Study of Onasemnogene Abeparvovec to Treat Children and Young Adults with Spinal Muscular Atrophy (SMA)

            Novartis Reports Data from P-III (STEER) Study of Onasemnogene Abeparvovec to Treat Children and Young Adults with Spinal Muscular...

            • December 30, 2024
            Novartis Reports Longer-Term Results from P-III (NATALEE) Trial of Kisqali (Ribociclib) to Treat Early Breast Cancer

              Novartis Reports Longer-Term Results from P-III (NATALEE) Trial of Kisqali (Ribociclib) to Treat Early Breast Cancer

              • December 11, 2024
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.